Eli Lilly is racing to market donanemab for Alzheimer’s after Eisai and Biogen’s drug for the disease, Leqembi, won FDA approval this month.

But settling soon seems unlikely, Diller said, since “there’s no trust between the parties.”

Ford said lower mineral costs and an expected production boost allowed it to cut the electric truck’s prices.